Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-05-22

Clinical Trial Update: Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD [Phase 2]

View source ↗

Summary

Phase 2 trial investigating lanthanum carbonate effects on FGF-23 in subjects with stage 3 chronic kidney disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LANTHANUM CARBONATE (lanthanum carbonate)

Snippet

Sponsor: Shire | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2013-05-22